- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04022057
The Impact of a Preoperative Nerve Block in Foot and Ankle Surgery on the Consumption of Sevoflurane
Reconstructive foot and ankle surgery is performed under general anesthesia. Included in this spectrum of surgery are ankle arthroplasties, various fusions, corrective arthrodesis, and more. Pain control for after the surgery can be achieved purely with intravenous and oral pain medication or in combination with freezing of the nerves. Nerve freezing (nerve block) placed before surgery has the potential to substantially reduce the amount of inhaled anesthetic given to the patient during surgery. This can benefit the patient with being more awake and crisp more quickly after surgery. It can also reduce cost to the system. A further benefit which has received very little attention so far, is that reducing the amount of inhaled anesthetic given also lowers the environmental footprint created by the anesthetic. For the region of the foot and ankle to be fully frozen, both the sciatic nerve and the saphenous nerve must be successfully blocked. Sciatic nerve blockade is most commonly achieved by blocking the nerve in the popliteal fossa. This block is named popliteal nerve block.
The investigators will examine and quantify the amount of inhaled anesthetic used for each case and will compare how the consumption is affected by whether the nerve blocks are applied before or after surgery. Patients will have two nerve block catheters (popliteal and saphenous catheter) placed under ultrasound-guidance prior to the case by an experienced and specifically trained anesthesiologist. The catheters will be loaded with a solution to which the anesthesiologist is blinded. It will either be local anesthetic or 5% dextrose (sham). The general anesthetic will be conducted according to a research protocol with anesthetic depth being the targeted endpoint. Measurements of the required MAC-Value (minimum alveolar concentration) of inhaled anesthetic will be recorded every five minutes by a study team member. At the end of the case the anesthesiologist will be unblinded to the solution. Should the patient have received sham initially, they will now receive the full dose of local anesthetic prior to being woken up.
Study Overview
Status
Intervention / Treatment
Detailed Description
Following ethics approval, eligible patients meeting the inclusion/exclusion criteria will be consented in pre-assessment unit or day surgery at least 2 hours prior to surgery. Patients will then be randomized into two groups:
- Popliteal and saphenous nerve block catheter insertion with 10 mL 1% ropivacaine injection into each (Treatment group)
- Popliteal and saphenous nerve block catheter insertion with 10 mL 5% dextrose injection into each (Sham)
All syringes will be blinded to the anesthesiologist in the case. Each patient will have two syringes for before and for after surgery - one set for treatment and one sham. Depending on the randomization they will get first one before surgery and then the other after surgery. Popliteal and saphenous nerve block catheters will be inserted under ultrasound guidance using the catheter-over-needle technique whereby the location of the tip of the catheter can be easily determined. All nerve block catheters will be performed by experienced acute pain physicians who have been performing interscalene blocks under ultrasound guidance for at least 5 years. Successful catheter placement will be verified by following the spread of the injectate, which will occur just before induction of general anesthesia in the operating room. Induction of general anesthesia will follow a standardized protocol with the intravenous administration of sufentanil 0.2 mcg/kg, propofol 2 mg/kg, and rocuronium 0.5 mg/kg. General anesthesia will be maintained with sevoflurane, which will be age-adjusted to 1.0 minimum alveolar concentration (MAC) to begin the case and then adjusted from there as per protocol. Sedline, Masimo® will be used to monitor the depth of anesthesia. The intraoperative patient state index (PSI) target will be 25 - 50. As per protocol, adjustments of the age-adjusted MAC will be performed as follows at every measuring point:
A PSI of either below 25 or of over 50 will always be treated with an adjustment of the age-adjusted MAC value. The same is done if the heart rate and/or the blood pressure is outside of +/- 20% of baseline. The primary goal is to treat any of the above changes with an adjustment to the age-adjusted MAC value. The anesthesiologist will always be able to administer an analgesic, should this be clinically necessary. The patient will be given a bolus of 1 mcg/kg of remifentanil and this will be recorded. The age-adjusted MAC value will be recorded every 5 minutes until the anesthesiologist reduces the anesthetic in preparation for extubation. At the conclusion of surgery and before general anesthesia is ended, the patients will receive the second set of solutions injected into their catheters.
Postoperatively, patients will go to post-anesthesia care unit (PACU). The distribution of the sensory or motor block will then be checked and recorded 30 minutes after arriving in PACU in both groups. The numerical rating scale (NRS) for pain will also be recorded in PACU at 0, 15, 30 and 45 minutes. The patients will there be assessed by members of the acute pain service team and treated as necessary before being transferred to the ward.
The patient, operating room anesthesiologist and the data collection personnel will be blinded.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Timur JP Özelsel, MD, DESA
- Phone Number: 780-407-8861
- Email: ozelsel@ualberta.ca
Study Contact Backup
- Name: Rakesh V Sondekoppam, MD
- Phone Number: 780-407-8861
- Email: rakesh6282@gmail.com
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G2G3
- Recruiting
- University of Alberta Hospital
-
Contact:
- Rakesh V Sondekoppam, MD
- Phone Number: 780-407-8861
- Email: rakesh6282@gmail.com
-
Contact:
- Timur JP Özelsel, MD
- Phone Number: 780-407-8861
- Email: ozelsel@ualberta.ca
-
Principal Investigator:
- Timur JP Özelsel, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients undergoing elective reconstructive foot and ankle surgery
- Patients eligible for popliteal and saphenous nerve block
- All adults 18 years of age or older
- Capable to give consent
Exclusion Criteria:
- Patients who are unable to give consent
- Local anaesthetic allergy
- Hemidiaphragm paresis on the contralateral side to the block/surgery site
- Bleeding diathesis
- Coagulopathy
- Pre-existing neurological deficits
- Patients with a Body Mass Index >35
- Patients with significant comorbidities, physiological limitations, and allergies that are unable to tolerate the protocolized induction and maintenance of anesthesia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pre-GA
10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through both the popliteal and the saphenous catheter
|
Local anesthetic injection
Sham Injection
|
Sham Comparator: Post-GA
10 mL of 5% dextrose injection before the start of surgery and 10 ml of 1% ropivacaine injection at the end of surgery through both the popliteal and the saphenous catheter
|
Local anesthetic injection
Sham Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Age-adjusted MAC of sevoflurane per hour
Time Frame: Intraoperative measurement done at the end of anesthetic
|
The average age-adjusted end- tidal minimum alveolar concentration (MAC) will be calculated by averaging the end tidal MAC required to maintain the depth of anesthesia as measured by PSI between 25-50 intra-operatively.
This will be compared between the two groups.
|
Intraoperative measurement done at the end of anesthetic
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative opioid use
Time Frame: Intraoperative period
|
Intraoperative use of short acting opioid (in microgram/Kg) as per the study protocol will be recorded and compared between the two groups
|
Intraoperative period
|
The sedation score in PACU
Time Frame: 1st postoperative hour
|
Sedation scores will be recorded at 15 minute intervals based on Ramsay sedation scale (1-6) and will be compared between the two groups
|
1st postoperative hour
|
Intraoperative vasopressor usage
Time Frame: Intraoperative period
|
Amount and frequency of the intraoperative usage of vasopressor (phenylephrine in micrograms) will be documented and compared between the two groups
|
Intraoperative period
|
Intraoperative heart rate
Time Frame: Intraoperative period
|
Intraoperative heart rate (in beats/minute) will be documented at 5 minute interval and compared between the two groups
|
Intraoperative period
|
Postoperative opioid use in PACU
Time Frame: Up to 24 postoperative hours
|
Total amount of opioids (in mg of morphine equivalents) in the PACU and over the first 24 postoperative hours will be recorded and compared between the two groups
|
Up to 24 postoperative hours
|
Maximum pain scores in the first 24 post-operative hours
Time Frame: Up to 24 postoperative hours
|
Maximum pain scores will be recorded using numerical rating scale (NRS) of 0-10 (where 0=no pain and 10= maximum pain) on arrival to PACU and at 0,15,30, 45 minutes and at 24 postoperative hours and compared between the two groups
|
Up to 24 postoperative hours
|
Nausea and vomiting in the first 24 post-operative hours
Time Frame: Up to 24 postoperative hours
|
Nausea scores (on a Likert scale of 1-4 where 1 = no nausea, 2= mild nausea, 3= moderate nausea and 4= severe nausea/vomiting will be recorded on arrival to PACU and at 0,15,30, 45 minutes and at 24 postoperative hours and will be compared between the two groups
|
Up to 24 postoperative hours
|
24 hour opioid consumption
Time Frame: Up to 24 postoperative hours
|
Total consumption of opioids (in morphine equivalents) over the first 24 postoperative hours will be recorded and compared between the two groups
|
Up to 24 postoperative hours
|
Sensory testing of nerves in the distribution of the nerve block ("Cold test")
Time Frame: 1st postoperative hour
|
Sensory testing of the L2-S4 dermatomes will be performed in the PACU at 30 minutes of arrival to PACU to document the success of the block
|
1st postoperative hour
|
Intraoperative Mean blood pressure
Time Frame: Intraoperative period
|
Intraoperative mean blood pressure (in mm Hg) will be documented at 5 minute interval and compared between the two groups
|
Intraoperative period
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Vivian HY Ip, MD, University of Alberta
- Study Chair: Rakesh V Sondekoppam, MD, University of Alberta
- Study Director: Lora Pencheva, MD, University of Alberta
- Principal Investigator: Timur JP Özelsel, MD, DESA, University of Alberta
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00092857
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anesthesia; Functional
-
Hormozgan University of Medical SciencesUnknownAnesthesia | Anesthesia; FunctionalIran, Islamic Republic of
-
Universiti Sains MalaysiaCompletedAnesthesia | Anesthesia; FunctionalMalaysia
-
Taipei Veterans General Hospital, TaiwanNot yet recruitingAnesthesia | Drug Interaction | Anesthesia; FunctionalTaiwan
-
San Salvatore Hospital of L'AquilaRecruitingAnesthesia, Local | Anesthesia; Functional | Spinal CordItaly
-
Seoul National University HospitalCompletedAnesthesia; FunctionalKorea, Republic of
-
Shahid Beheshti University of Medical SciencesCompleted
-
Complexo Hospitalario Universitario de A CoruñaCompletedAnesthesia; FunctionalSpain
-
Fundación Pública Andaluza Progreso y SaludCompleted
-
Attikon HospitalCompletedAnesthesia; FunctionalGreece
-
Seoul National University HospitalUnknown
Clinical Trials on Ropivacaine injection
-
Hvidovre University HospitalUnknownPain, PostoperativeDenmark
-
Chuncheon Sacred Heart HospitalNot yet recruiting
-
Chuncheon Sacred Heart HospitalNot yet recruitingAnterior Cruciate Ligament Rupture | Femoral Nerve BlockKorea, Republic of
-
Chuncheon Sacred Heart HospitalNot yet recruiting
-
Chuncheon Sacred Heart HospitalNot yet recruitingAnterior Cruciate Ligament Rupture | Femoral Nerve BlockKorea, Republic of
-
Zhujiang HospitalCompletedGastrointestinal DiseaseChina
-
Henri Mondor University HospitalNot yet recruitingNeurologic Disorder | Gait, Hemiplegic | Block | Spastic Hemiplegia
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de BruxellesWithdrawnNerve Entrapment Syndrome | Cluneal SyndromeBelgium
-
University of PittsburghTerminatedOpioid Tolerance, Opioid Naive, Opioid ExposureUnited States
-
Vanderbilt University Medical CenterDuke UniversityWithdrawnMastectomy | Nerve Block | Analgesia, PostoperativeUnited States